Track market-moving stories before they get noisy

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting.

Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript

Bausch Health: A Buyout Bid Could Be the Ticket to Unlock ValueBausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.

The company also reported Phase Ib results for BL1332, an ocular surface pain candidate designed to block the TRPV1 receptor. The study met its primary endpoint in a capsaicin-induced pain model in healthy volunteers, according to the company.

Get Bausch + Lomb alerts:

It’s Time To Nibble On These Two Recent IPOs Chief Executive Officer Brent Saunders said the two programs represent “more than $2 billion in combined potential peak sales” and could provide growth opportunities beyond 2028. He said neither program is expected to launch within the company’s previously outlined three-year plan, though the associated clinical-development spending had been anticipated.

Dry Eye Candidate Shows Earlier Effect Bausch + Lomb’s dual-action eye drop combines the active ingredients in MIEBO and XIIDRA. MIEBO’s active ingredient, perfluorohexyloctane, or PFHO, is intended to reduce tear evaporation, while XIIDRA’s active ingredient, lifitegrast, acts as an anti-inflammatory.

Mayssa Attar, head of pharmaceutical R&D, said the four-week randomized, double-masked, active-controlled study enrolled 443 patients across six treatment and vehicle-control arms. The prespecified primary endpoint was change from baseline in total corneal fluorescein staining at day 29 compared with lifitegrast alone.

The combination treatment was numerically better than lifitegrast at day 29 but did not achieve statistical significance. However, at the prespecified day 15 assessment, the dual-action drop significantly reduced corneal staining versus lifitegrast alone, with a p-value of 0.0007.

At day 15, 41.6% of patients receiving the dual-action drop achieved a three-unit improvement in corneal staining, compared with 18.8% for lifitegrast alone and 31.6% for PFHO alone. The company said the combination treatment was administered twice daily, compared with four daily doses for PFHO alone, and used a 12-microliter drop volume versus 35 microliters in the lifitegrast-alone arm.

Attar said the combination numerically outperformed lifitegrast across several symptom-resolution measures, including itching, light sensitivity, blurred vision, irritation, burning and foreign-body sensation. Results versus PFHO were mixed, with the combination performing better on some measures and comparably or slightly below PFHO on others.

No new safety signals were observed, the company said. Instillation-site irritation occurred in 11.9% of patients receiving the combination therapy, compared with 21.2% for lifitegrast alone, while dysgeusia occurred in 10.9% and 15.2% of patients, respectively.

Yehia Hashad, Bausch + Lomb’s head of R&D, said the company expects to use day 15 as the primary endpoint in its next trial, while continuing to assess later time points. Management said it plans to use modeling and simulation work to determine the Phase III dose and dosing frequency.

During the question-and-answer session, Hashad said total corneal fluorescein staining has been used as an approvable endpoint in other programs. He added that the company has not yet said it has received FDA agreement on a 15-day corneal-staining endpoint, stating that it expects to speak with the agency.

BL1332 Pain Study Meets Primary Endpoint BL1332 is a topical TRPV1 antagonist intended to interrupt pain signaling on the ocular surface. According to the company, the molecule is approximately 100 times more potent and more water-soluble than its earlier-generation TRPV1 candidate, BL-1312.

The Phase Ib trial consisted of two parts. In the first, six healthy participants were used to identify a capsaicin concentration that produced a target pain response. In the second, 22 participants entered a double-masked, two-period crossover study in which each participant received BL1332 and a vehicle placebo on separate occasions.

The primary endpoint measured pain intensity five seconds after a capsaicin challenge. Mean pain intensity was 0.6 for BL1332 and 6.1 for vehicle, a statistically significant difference, the company said.

68.2% of participants receiving BL1332 reported complete pain resolution, compared with none receiving vehicle. Mean pain duration was 1.6 seconds for BL1332 versus 37.8 seconds for vehicle. No participants on BL1332 reported severe pain, defined as a score of 7 or higher, while more than one-third of vehicle-treated participants did. Attar said no treatment-emergent adverse events, serious adverse events or discontinuations were reported in either eye during the study. She also said an earlier Phase I study designed to assess systemic exposure and thermoregulatory safety found no hyperthermia, an issue that had affected earlier systemic TRPV1 antagonist programs.

Bausch + Lomb expects Phase II results for BL1332 in post-surgical ocular pain later in the year. Management said the Phase Ib findings support evaluating the candidate in additional acute and chronic ocular pain conditions, including pain associated with dry eye disease.

About Bausch + Lomb (NYSE:BLCO)Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Bausch + Lomb Right Now?Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDT

Company Participants

George Gadkowski - VP & Head of Investor Relations & Business Insights
Brenton L. Saunders - CEO & Chairman
Osama Eldessouky - Executive VP & CFO
Luc Bonnefoy - President of Surgical
Yehia Hashad - Executive VP of Research & Development and Chief Medical officer

Conference Call Participants

Patrick Wood
Young Li - Jefferies LLC, Research Division
Lei Huang - Wells Fargo Securities, LLC, Research Division
Douglas Miehm - RBC Capital Markets, Research Division
Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Good morning, and welcome to Bausch + Lomb's Second Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to George Gadkowski, Vice President of Investor Relations and Business Insights. Please go ahead.

George Gadkowski
VP & Head of Investor Relations & Business Insights

Thank you. Good morning, everyone, and welcome to our second quarter 2026 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Brent Saunders; Chief Financial Officer, Mr. Sam Eldessouky; and President of Surgical, Mr. Luc Bonnefoy. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

Before we begin, I would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking legend at the beginning of our presentation as it contains important information.

This presentation contains non-GAAP financial measures and ratios. For more information about these measures and ratios, please refer to Slide 1 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our

Bausch Health: A Buyout Bid Could Be the Ticket to Unlock ValueBausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity supported margin expansion and stronger cash generation.

Total second-quarter revenue was $1.394 billion, up 8% on a constant-currency basis. Foreign exchange provided an approximately $12 million revenue tailwind. Adjusted EBITDA increased 28% year over year on a reported basis to $246 million, while adjusted EBITDA margin rose 260 basis points to 17.6%.

Get Bausch + Lomb alerts:

It’s Time To Nibble On These Two Recent IPOs “Revenue growth and margin expansion are now also translating into stronger cash generation and deleveraging to strengthen the balance sheet,” Chief Financial Officer Sam Eldessouky said on the company’s earnings call.

Cash flow, margins and outlook Adjusted cash flow from operations totaled $161 million in the quarter, compared with $45 million in the first quarter, according to Chairman and Chief Executive Officer Brent Saunders. Adjusted free cash flow was $90 million after $71 million in capital expenditures. Net leverage stood at approximately 4.7 times at the end of the quarter, which the company said was a full-turn reduction from its Investor Day level.

Adjusted gross margin was 62.2%, up 160 basis points year over year, supported by a higher mix of premium products in pharmaceuticals and surgical, as well as productivity efforts. The company invested $114 million in adjusted research and development, an increase of 19% from the prior-year period. Adjusted SG&A margin improved by approximately 130 basis points.

Bausch + Lomb raised its 2026 revenue guidance by $20 million to a range of $5.440 billion to $5.540 billion. The outlook implies constant-currency growth of about 5.8% to 7.7%, 50 basis points above its prior outlook. The company cited a $25 million increase in its underlying business outlook, partly offset by a $5 million reduction in anticipated currency benefits.

The company also increased adjusted EBITDA guidance by $15 million to $1.025 billion to $1.075 billion. At the midpoint, the guidance implies an adjusted EBITDA margin of approximately 19.1% and adjusted EBITDA growth of approximately 18% year over year. Bausch + Lomb maintained expectations for about $365 million in interest expense, a 19% adjusted tax rate and approximately $285 million in full-year capital expenditures.

Saunders said deleveraging remains the company’s top capital-allocation priority, with a target of net leverage of 3.5 times or better by the end of 2028. The company said it would also evaluate investments that are immediately accretive and broadly neutral to leverage ratios.

Pharmaceuticals and vision care growth Pharmaceutical revenue was $354 million, up 14% from the prior year on a constant-currency basis. U.S. pharmaceuticals grew 17%, led by the dry-eye franchise, which increased 23%. MIEBO revenue rose 44% to $91 million, while XIIDRA revenue increased 6% to $87 million.

Saunders said MIEBO’s Medicare coverage increased to 88% from 71% after the addition of Humana Medicare coverage. He also said the company expects MIEBO to become the branded industry leader in dry-eye treatment, though the company did not provide a specific timeline.

International pharmaceuticals grew 8%. Bausch + Lomb expects a top-line data readout for its dual-action dry-eye candidate near the end of the third quarter. Yehia Hashad, executive vice president of research and development and chief medical officer, said the Phase 2 study is evaluating efficacy and safety of the combination therapy, including whether it demonstrates superiority over each individual component. If results support advancement, the company plans to begin Phase 3 studies in 2027.

Vision care revenue was $784 million, up 4%. Consumer revenue increased 3%, while contact lens revenue grew 5%. The consumer dry-eye portfolio generated $123 million in revenue, up 5%, including 12% growth for Blink and 3% growth for Artelac. LUMIFY revenue was $63 million, up 2%, while PreserVision and Ocuvite eye vitamins generated $104 million, up 1% on a reported basis.

The company said consumer demand strengthened during the quarter and continued into July. Saunders noted that retail consumption trends have tracked closely with gasoline prices, with some consumers trading down to smaller pack sizes or showing greater promotional sensitivity during periods of pressure.

Contact lens growth was broad-based across product lines and geographies. Daily silicone hydrogel products grew 16%, Biotrue rose 13% and ULTRA increased 9%. U.S. contact lens revenue grew 5%, while international revenue increased 6%, including 11% growth in EMEA and Canada, 7% in Latin America and 3% in Asia-Pacific.

Surgical business gains momentum Surgical revenue was $256 million, up 16% year over year and 17% compared with the second quarter of 2024, which the company characterized as its pre-recall baseline. Implantables grew 64% year over year and 37% versus the 2024 comparison period. Premium intraocular lens revenue increased 175%.

Luc Bonnefoy, president of surgical, said premium eyewear represented 13% of surgical revenue in the second quarter, compared with 9% in 2025, 7% in 2024 and 6% in 2023. He attributed the mix shift to the company’s premium IOL portfolio and field-force execution, as well as manufacturing and supply-network initiatives.

The company filed an FDA submission during the quarter for ELIOS, its implant-free minimally invasive glaucoma surgery excimer laser. Management said it expects approval in the second half of 2026. Hashad said clinical-trial results over two years showed more than 80% of patients treated with ELIOS were drop-free.

Bausch + Lomb also said it remains on track to submit enVista Beyond by the end of 2026 and expects approval by the end of 2027. Hashad said the company had received an initial set of data and was continuing its analysis, but remained confident in the overall data seen so far.

About Bausch + Lomb (NYSE:BLCO)Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Bausch + Lomb Right Now?Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec.

-

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

Wednesday, July 29, 2026

  Time:

8 a.m. ET

  Webcast:

https://www.webcaster5.com/Webcast/Page/2883/53394

  Participant Event Dial-in:

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

  Participant Access Code:

415531

  Replay Dial-in:

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

  Replay Passcode:

53394 (replay available until Aug. 12, 2026)

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2026 Bausch + Lomb.

More News From Bausch + Lomb Corporation

Back to Newsroom

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

Posted by Defense World Staff on Mar 30th, 2026

Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 4,006,617 shares, a growth of 50.7% from the February 26th total of 2,659,462 shares. Based on an average trading volume of 422,793 shares, the short-interest ratio is presently 9.5 days. Approximately 1.1% of the shares of the company are short sold.

Analysts Set New Price Targets Several research analysts recently commented on BLCO shares. Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the stock an “in-line” rating in a report on Monday, January 5th. Wall Street Zen downgraded Bausch + Lomb from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $19.00 price objective on shares of Bausch + Lomb in a research note on Friday, January 9th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $18.00 price objective on shares of Bausch + Lomb in a research report on Thursday, February 19th. Finally, Stifel Nicolaus set a $16.00 target price on Bausch + Lomb in a research note on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $18.25.

Read Our Latest Report on BLCO

Insider Buying and Selling In related news, EVP A Robert D. Bailey bought 14,600 shares of Bausch + Lomb stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average cost of $17.15 per share, for a total transaction of $250,390.00. Following the acquisition, the executive vice president owned 231,890 shares in the company, valued at $3,976,913.50. This trade represents a 6.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Brent L. Saunders purchased 14,700 shares of the stock in a transaction on Friday, March 6th. The shares were bought at an average price of $17.14 per share, for a total transaction of $251,958.00. Following the acquisition, the chief executive officer owned 966,575 shares of the company’s stock, valued at approximately $16,567,095.50. The trade was a 1.54% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 33,300 shares of company stock worth $570,868. 0.15% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch + Lomb A number of hedge funds and other institutional investors have recently made changes to their positions in BLCO. Caitong International Asset Management Co. Ltd increased its stake in Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after acquiring an additional 1,136 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the period. Wells Fargo & Company MN boosted its holdings in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after purchasing an additional 1,403 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Bausch + Lomb by 55.3% during the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock valued at $132,000 after purchasing an additional 3,246 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Bausch + Lomb in the 4th quarter valued at approximately $178,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Stock Performance BLCO opened at $15.38 on Monday. The stock’s 50 day simple moving average is $17.02 and its 200-day simple moving average is $16.31. The company has a current ratio of 1.55, a quick ratio of 1.04 and a debt-to-equity ratio of 0.77. The stock has a market cap of $5.46 billion, a PE ratio of -15.08, a P/E/G ratio of 0.64 and a beta of 0.58. Bausch + Lomb has a 1 year low of $10.45 and a 1 year high of $18.92.

Bausch + Lomb (NYSE:BLCO – Get Free Report) last issued its earnings results on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.38 billion. During the same period last year, the business earned $0.25 earnings per share. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. Sell-side analysts forecast that Bausch + Lomb will post 0.74 EPS for the current year.

About Bausch + Lomb (Get Free Report)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

Recommended Stories Five stocks we like better than Bausch + Lomb Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBrokerages Set Alvotech (NASDAQ:ALVO) Price Target at $7.60

NEXT HEADLINE »Clean Power Hydrogen (LON:CPH2) Trading 3.9% Higher – Still a Buy?

Posted by Defense World Staff on Mar 31st, 2026

Shares of Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) have been given an average recommendation of “Hold” by the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $18.25.

A number of brokerages have issued reports on BLCO. The Goldman Sachs Group reiterated a “neutral” rating and set a $19.00 price objective on shares of Bausch + Lomb in a research note on Friday, January 9th. Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the company an “in-line” rating in a research report on Monday, January 5th. Royal Bank Of Canada upped their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Tuesday, January 27th. Barclays lifted their price objective on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Finally, Citigroup boosted their price objective on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, February 19th.

View Our Latest Report on Bausch + Lomb

Bausch + Lomb Price Performance Bausch + Lomb stock opened at $15.24 on Tuesday. The firm has a market cap of $5.41 billion, a PE ratio of -14.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.55 and a quick ratio of 1.04. The stock’s fifty day moving average price is $16.98 and its two-hundred day moving average price is $16.31. Bausch + Lomb has a one year low of $10.45 and a one year high of $18.92.

Bausch + Lomb (NYSE:BLCO – Get Free Report) last released its earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the previous year, the company posted $0.25 earnings per share. The business’s revenue was up 9.8% compared to the same quarter last year. As a group, research analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Insider Activity In other Bausch + Lomb news, CEO Brent L. Saunders purchased 14,700 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were bought at an average price of $17.14 per share, for a total transaction of $251,958.00. Following the purchase, the chief executive officer owned 966,575 shares in the company, valued at approximately $16,567,095.50. This trade represents a 1.54% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sam Eldessouky purchased 4,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $17.13 per share, with a total value of $68,520.00. Following the acquisition, the chief financial officer directly owned 403,130 shares in the company, valued at $6,905,616.90. This represents a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 33,300 shares of company stock worth $570,868. Insiders own 0.15% of the company’s stock.

Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Oaktree Capital Management LP bought a new stake in shares of Bausch + Lomb during the 2nd quarter valued at approximately $32,801,000. Goldentree Asset Management LP lifted its stake in Bausch + Lomb by 3.0% in the 3rd quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company’s stock valued at $40,002,000 after purchasing an additional 77,323 shares during the last quarter. Compass Rose Asset Management LP boosted its position in Bausch + Lomb by 22.0% in the third quarter. Compass Rose Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $15,070,000 after buying an additional 180,000 shares in the last quarter. Handelsbanken Fonder AB acquired a new stake in Bausch + Lomb in the second quarter valued at approximately $202,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Bausch + Lomb during the third quarter worth $2,249,000. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb (Get Free Report)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

See Also Five stocks we like better than Bausch + Lomb

Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEONE Gas, Inc. (NYSE:OGS) Receives Average Recommendation of “Hold” from Brokerages

NEXT HEADLINE »Pembina Pipeline Co. (TSE:PPL) Receives Consensus Recommendation of “Hold” from Analysts

Posted by Defense World Staff on Apr 10th, 2026

Biodesix (NASDAQ:BDSX – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.

Insider & Institutional Ownership 21.0% of Biodesix shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 30.1% of Biodesix shares are owned by company insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk Biodesix has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Profitability This table compares Biodesix and Bausch + Lomb’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Biodesix -39.85% -1,760.83% -40.28% Bausch + Lomb -7.06% 2.77% 1.31% Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Biodesix and Bausch + Lomb, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 0 5 0 2.67 Bausch + Lomb 1 10 4 0 2.20 Biodesix currently has a consensus target price of $32.50, indicating a potential upside of 143.99%. Bausch + Lomb has a consensus target price of $18.25, indicating a potential upside of 10.94%. Given Biodesix’s stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Bausch + Lomb.

Earnings & Valuation This table compares Biodesix and Bausch + Lomb”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50 million 1.48 -$35.26 million ($4.85) -2.75 Bausch + Lomb $5.10 billion 1.15 -$360.00 million ($1.02) -16.13 Biodesix has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Summary Biodesix beats Bausch + Lomb on 8 of the 14 factors compared between the two stocks.

About Biodesix (Get Free Report)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About Bausch + Lomb (Get Free Report)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECritical Contrast: A.P. Moller-Maersk (OTCMKTS:AMKBY) & Frontline (NYSE:FRO)

NEXT HEADLINE »Analyzing Bonk (NASDAQ:BNKK) and Caring Brands (NASDAQ:CABR)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of its 2025 Sustainability Impact Report, outlining progress against its environmental, social and governance priorities and introducing The Broader Perspective, the company's sustainability framework designed to guide future action and accountability. Anchored in the belief that seeing the full pict.

Bausch + Lomb (BLCO - Free Report) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +43.37%. A quarter ago, it was expected that this company would post earnings of $0.35 per share when it actually produced earnings of $0.32, delivering a surprise of -8.57%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Bausch + Lomb, which belongs to the Zacks Medical Services industry, posted revenues of $1.24 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.33%. This compares to year-ago revenues of $1.14 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Bausch + Lomb shares have lost about 8% since the beginning of the year versus the S&P 500's gain of 4.3%.

What's Next for Bausch + Lomb?While Bausch + Lomb has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Bausch + Lomb was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.15 on $1.37 billion in revenues for the coming quarter and $0.78 on $5.43 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Sotera Health Company (SHC - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.

This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +21.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Sotera Health Company's revenues are expected to be $271.98 million, up 6.9% from the year-ago quarter.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company's broad portfolio of products.

© RaihanaAsral / Getty Images

With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets. Healthcare keeps that promise. Personal healthcare spending climbed from $3.432 trillion in January 2025 to $3.741 trillion by March 2026, outpacing total consumption while motor vehicles and other discretionary categories softened. Medical device stocks trading below $30 give individual investors an affordable way to ride that resilience.

With that in mind, here are two medical device stocks under $30 that look attractive on fundamentals, guidance and capital-return policy heading into the back half of 2026.

Envista (NYSE: NVST) Envista (NYSE:NVST | NVST Price Prediction) is a dental products holding company whose brands include DEXIS, Kerr, Nobel Biocare, Ormco and Spark clear aligners.

Shares closed at $24.28 on May 12, 2026, up 11.84% year to date and 30.89% over the past year, which keeps the name well inside the sub-$30 bucket. The most recent quarter strengthens the case. Q1 FY26 revenue of $705.5 million grew 14.4% year over year and beat consensus by 3.74%, while adjusted EPS of $0.36 topped the $0.3132 estimate by 14.94%. Adjusted EBITDA rose 25% to $98.9 million, and management reaffirmed full-year adjusted EPS guidance of $1.35 to $1.45.

The bull case is straightforward. Core revenue expanded across every major business, Spark aligners turned profitable in the second half of 2025, and the board authorized a new $300 million share buyback running through December 31, 2029. CEO Paul Keel called the quarter “a good start to 2026” with momentum carrying into the back half. The leadership team also received broad equity awards in February, a signal of internal confidence at recent price levels.

The key risk: free cash flow swung to negative $15.7 million in Q1, and management flagged tariff exposure plus pricing pressure from China’s volume-based procurement program. Those are real headwinds, but they sit against guided adjusted EBITDA growth of 7% to 13%. For investors who want dental exposure with a clear capital-return story, Envista screens well at this price.

Bausch & Lomb (NYSE: BLCO) Bausch & Lomb (NYSE:BLCO) is an eye health company selling contact lenses, surgical implants and prescription pharmaceuticals across the MIEBO, XIIDRA, LUMIFY and PreserVision brands.

The stock changed hands at $16.03 on May 12, 2026, off 6.15% year to date but up 34.82% over the past year. That pullback looks more like consolidation than rejection. Q1 FY26 revenue reached $1.244 billion, up 9.4% year over year, and the company swung to $33 million in operating income from an $83 million loss a year earlier. Adjusted EPS of $0.05 came in 6.72% below consensus, yet management still raised full-year revenue guidance to $5.420 billion to $5.520 billion and adjusted EBITDA to $1.010 billion to $1.060 billion.

The growth engine is pharmaceuticals. MIEBO grew 33% and XIIDRA grew 30%, lifting the segment 14%. CEO Brent Saunders said the company is “driving sustainable growth and margin expansion”, and H.C. Wainwright carries a Buy rating with a $20 price target. Four independent directors also bought shares at $15.90 on April 30, 2026, a tangible vote of confidence right near the current quote.

The principal risk is structural. Bausch & Lomb is still working through its separation from Bausch Health Companies, carries roughly $97 million in quarterly interest expense and continues to post GAAP losses. Tariff policy could also pressure the international book. For investors comfortable with a leveraged separation story, the eye-care franchise has visible momentum.

Envista and Bausch & Lomb both pair growth with real balance-sheet questions, so position size, time horizon and personal risk tolerance still matter. Read the filings, watch the next quarter and decide what actually fits your portfolio.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av.

Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript